Glovax's perspective: opportunities and approaches to vaccine business in Asia.
Glovax Co., Ltd. has focused on regional population needs, and assessed potentially interesting vaccine candidates for their safety, efficacy and cost-effectiveness. Economic analysis was made to identify the area of high commercial potential based on quantity demands and pricing flexibility. Epidemiological data on the target diseases were reviewed so that we could identify the vaccines of more limited interests worldwide but still of high significance in regional public health. Several viral vaccine products were selected as our priority including Japanese encephalitis and Hepatitis A vaccines. Extensive safety and clinical studies have been projected. To ensure that a safe and effective vaccine be supplied at the same quality level, new manufacturing facilities are being constructed in our region. Several approaches have been made to overcome technical, financial, and managerial obstacles. Close partnerships with industry, biomedical community and regulatory agencies may enhance the viability of our approach to be a successful vaccine player in this region.